Design, synthesis, and biological evaluation of novel nicotinamide derivatives as potential histone deacetylase-3 inhibitors
- 20 May 2020
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 44 (23) , 9671-9683
Abstract
Most of the FDA approved histone deacetylase inhibitors (HDACi) contain hydroxamate as the zinc binding group (ZBG). Hydroxamates form strong electrostatic metal chelation with divalent zinc present in HDAC. This strong zinc chelation leads to unwanted metabolic abnormalities. Therefore, the design of a non-hydroxamate moiety as a ZBG encourages medicinal chemistry researchers. Here, a series of nicotinamide derivatives have been designed and synthesized as HDACi. All compounds were tested for their inhibitory activities against pan HDACs (containing predominantly HDAC1 and HDAC2 isozymes) and against the HDAC3 isoform. Among these, compounds 6b and 6n showed comparable pan HDAC inhibitory activity (IC50 = 4.648 μM and IC50 = 5.481 μM, respectively) compared with BG45 (IC50 = 5.506 μM). Compound 6b exhibited the best potency against HDAC3 with IC50 = 0.694 μM. In addition, the anti-proliferative activity of the synthesized compounds 6a–s was evaluated against three different cancer cell lines including B16F10, MCF-7, and A549. Compound 6b displayed the highest anti-proliferative potency (IC50 = 4.66 μM in B16F10 cell lines) and compounds 6b, 6c, 6h, 6i, 6l, 6m, and 6n exhibited higher cytotoxicity against all cell lines compared with the reference BG45. The selected potent compounds also displayed significant selectivity against cancer cell lines over normal human embryonic kidney (HEK-293) cell lines. The molecular modelling study displayed possible interactions between the most potent inhibitor 6b and HDAC3 active sites. Furthermore, the predicted in silico studies of all target compounds revealed acceptable physicochemical properties and pharmacokinetic parameters.Keywords
Funding Information
- Anusandhan National Research Foundation (EMR/2016/001411)
- Council of Scientific and Industrial Research, India
This publication has 34 references indexed in Scilit:
- Design and synthesis of imidazole based zinc binding groups as novel small molecule inhibitors targeting Histone deacetylase enzymes in lung cancerJournal of Molecular Structure, 2020
- Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitorsEuropean Journal of Medicinal Chemistry, 2020
- Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicityEuropean Journal of Pharmacology, 2020
- Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screeningEuropean Journal of Medicinal Chemistry, 2020
- Inhibitors of histone deacetylase as antitumor agents: A critical reviewBioorganic Chemistry, 2016
- HDACs link the DNA damage response, processing of double-strand breaks and autophagyNature, 2011
- Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?Nature Reviews Cancer, 2006
- Histone metabolic pathways and chromatin assembly factors as proliferation markersCancer Letters, 2005
- Molecular Evolution of the Histone Deacetylase Family: Functional Implications of Phylogenetic AnalysisJournal of Molecular Biology, 2004
- The Hallmarks of CancerCell, 2000